SAN DIEGO, CA--(Marketwire - Dec 4, 2012) - Invivoscribe Technologies, Inc., a privately-held life science company based in San Diego, California, announces the launch of Genection, Inc.

Genection provides physicians with a dedicated online platform for global access to the entire clinically-actionable genetic test menu, including both routine and esoteric genetic tests, exome and whole genome sequencing, cancer somatic mutation testing, and pharmacogenomics.

Genection's model is not payor driven, so prescribing physicians have access to genetic tests that may currently be unavailable, overlooked, or even inaccessible through their patients' managed care plans and health care institutions. Combine this comprehensive genetic test offering with convenient online ordering, seamless linking of multiple CLIA and CAP accredited laboratories for reporting and interpretation and integrated service offerings such as next generation sequencing and advanced bioinformatics in a singular location and Genection is streamlining the entire diagnostic pipeline.

"Genection is a valuable tool in the personalized molecular medicine landscape. Clinicians spend too much of their time identifying and ordering clinically relevant genetic tests, while struggling to keep abreast of the flood of clinical information around new biomarkers," said Bradley Patay, M.D., Genection's Chief Medical Officer. "In addition to thebroad selectionof genetic tests available to order through their service, Genection offers one of the most relevant new genomic testing servicesnext generation sequencing used to detect driver mutations in cancer."Oncologists appreciate that current more effective and individualized cancer treatment programs require improved diagnostic stratification of their patients. Using targeted gene assays for deep sequencing of oncogenes and tumor suppressor genes, and exome sequencing to identify rare or unknown genes that may contribute to an individual's cancer, an oncologist can better identify the underlying cause of a patient's tumor to create a more targeted treatment plan.

Genection has agreements in place with several top CLIA and CAP accredited laboratories as well as sequencing centers."Our initial partners include ARUP Laboratories, Foundation Medicine, Cypher Genomics, the Laboratory for Personalized Molecular Medicine (LabPMM) in the U.S., as well as its ISO15189 compliant laboratory (LabPMM GmbH) in Martinsried, Germany," said Suzanne Graham, Genection's Senior Manager of Business Development. "Genection also has established relationships with sequencing providers, including Illumina and Ambry Genetics." Moreover, Genection has alliances with a consortium of genetic counselors, to provide current informed decision making support, reducing costs of the informed consent process, and helping to avoid unnecessary testing.

What does this integration mean for a physician and their patient?

"In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of healthcare.Genection's mission seeks to accelerate this adoption process," Dr. Patay continued. "The combination of CLIA-validated genetic testing, whole exome or whole genome sequencing and broad targeted assays, along with critical bioinformatics, analytic tools, and interpretative guidelines will contribute to timely definitive diagnoses for patients with rare, unexplained diseases or complex diseases; in essence, this integration will speed delivery of genomic test results and improve patient care."

More than just facilitating ordering and transmitting patient reports and data, Genection's service is designed to vastly improve the communication between genetic counselors, physicians and patients. The Genection web application provides HIPAA compliant, secure patient data management for physicians and health organizations. As patient care moves to more team-based management, it is vital for patient information to integrate with several clinicians, and not be limited to one single provider.Genection streamlines this process, allowing clinicians to share test results and genetic information with other healthcare providers, which can assist in a diagnosis for a patient and accelerate creation of individualized treatment plans and potentially life-saving therapies.

Genection also serves as the gateway for the global Together We Cure initiative, which allows acute myeloid leukemia (AML) patients and physicians to share clinical information to facilitate more rapid development of AML targeted therapeutics.

Genection is a privately held company owned by Invivoscribe Technologies, Inc., founded 18 years ago by its Chairman & CEO, Jeffrey E. Miller, Ph.D.Dr. Miller will serve as President of Genection.Bradley A. Patay, MD is Genection's Chief Medical Officer, and Suzanne M. Graham, Ph.D., is Senior Manager of Business Development.

Read more from the original source:

Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire ...

( Centro Nacional de Investigaciones Oncologicas (CNIO) ) A team of scientists from the Spanish National Cancer Research Centre, led by its director, María Blasco, together with Jose M. Mato, the director of the Center for Cooperative Research in Biosciences, has shown that the metabolic profile of an organism indicates its level of cellular aging and the general state of health in mice.

Visit link:

Metabolic biomarkers for preventive molecular medicine

NEW YORK (GenomeWeb News) – Phoenix Children's Hospital said today that it has launched a new molecular and personalized medicine research institute, working with the and other partners, that will focus first on childhood cancers but later will branch out into other research directions.

See the original post here:

Phoenix Children's Hospital Creating $50M Molecular Medicine Institute

Newswise Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the bodys natural defenses into overdrive, actually intensifying illness while fighting infection.

The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C. diff. It has been linked to the death of 14,000 Americans annually, according to the Centers for Disease Control and Prevention.

Researchers with the Center for Modeling Immunity to Enteric Pathogens at Virginia Tech applied computational and mathematical modeling in combination with RNA-sequencing and mouse studies to understand an important regulatory pathway during Clostridium difficile infection.

"We have found that tissue damage and disease severity in C. difficile infection is associated with a disruption of the peroxisome proliferator-activated receptor gamma (PPAR) pathway," said Josep Bassaganya-Riera, a professor of immunology, director of the Nutritional Immunology and Molecular Medicine Laboratory and the principal investigator with the Center for Modeling Immunity to Enteric Pathogens.

The human intestine must peacefully coexist with trillions of beneficial bacteria while swiftly responding to pathogens such as C. difficile. Sometimes the immune system will go into overdrive when responding to pathogens, causing more damage in an attempt to clear the infection.

Scientists studying mice bowels found the PPAR pathway keeps the immune response in check, allowing the body to heal while the immune cells that fight infection do their work in a controlled manner. When PPAR was absent or inactive, disease was more rampant and colonic lesions from C. difficile were much worse.

In addition, researchers found the protective mechanism can be activated and the severity of the C. difficile infection can be reduced by using an existing diabetes drug. More studies will be needed before the drug can be tested against C. difficile.

"This research demonstrates that the integration of powerful computer simulations of host responses with immunology experimentation not only contributes to a better understanding of the immunoregulatory processes in the gut mucosa during C. difficile infection, but it also advances the discovery of broad-based therapeutic targets in the host for infectious diseases," said Raquel Hontecillas, an assistant professor of immunology at Virginia Tech, co-director of the Nutritional Immunology and Molecular Medicine Laboratory and leader of the immunology component of the Center for Modeling Immunity to Enteric Pathogens.

The study builds on previous work from the Nutritional Immunology and Molecular Medicine Laboratory, which shows that PPAR is critical to reducing disease caused by enteric pathogens and regulating autoimmune diseases such as inflammatory bowel disease.

"With continued research, new drugs targeting this pathway will be developed that will have fewer side effects and greater efficacy than those currently on the market," Bassaganya-Riera said.

Read the original here:

Potential Drug Target May Curb Hospital-Acquired Infection

Public release date: 30-Nov-2012 [ | E-mail | Share ]

Contact: Tiffany Trent ttrent@vt.edu 540-231-6822 Virginia Tech

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C. diff. It has been linked to the death of 14,000 Americans annually, according to the Centers for Disease Control and Prevention.

Researchers with the Center for Modeling Immunity to Enteric Pathogens at Virginia Tech applied computational and mathematical modeling in combination with RNA-sequencing and mouse studies to understand an important regulatory pathway during Clostridium difficile infection.

"We have found that tissue damage and disease severity in C. difficile infection is associated with a disruption of the peroxisome proliferator-activated receptor gamma (PPAR) pathway," said Josep Bassaganya-Riera, a professor of immunology, director of the Nutritional Immunology and Molecular Medicine Laboratory and the principal investigator with the Center for Modeling Immunity to Enteric Pathogens.

The human intestine must peacefully coexist with trillions of beneficial bacteria while swiftly responding to pathogens such as C. difficile. Sometimes the immune system will go into overdrive when responding to pathogens, causing more damage in an attempt to clear the infection.

Scientists studying mice bowels found the PPARy pathway keeps the immune response in check, allowing the body to heal while the immune cells that fight infection do their work in a controlled manner. When PPARy was absent or inactive, disease was more rampant and colonic lesions from C. difficile were much worse.

In addition, researchers found the protective mechanism can be activated and the severity of the C. difficile infection can be reduced by using an existing diabetes drug. More studies will be needed before the drug can be tested against C. difficile.

"This research demonstrates that the integration of powerful computer simulations of host responses with immunology experimentation not only contributes to a better understanding of the immunoregulatory processes in the gut mucosa during C. difficile infection, but it also advances the discovery of broad-based therapeutic targets in the host for infectious diseases," said Raquel Hontecillas, an assistant professor of immunology at Virginia Tech, co-director of the Nutritional Immunology and Molecular Medicine Laboratory and leader of the immunology component of the Center for Modeling Immunity to Enteric Pathogens.

The rest is here:

Researchers discover how C. diff red lines immune response

GRAND RAPIDS, MI -- Inside Ferris State Universitys newly renovated molecular diagnostics lab, students are learning the skills that administrators say will make them a perfect fit for clinical laboratories in West Michigan and beyond.

Located on the campus of Grand Rapids Community College, students at the lab are learning the techniques needed to use molecular technology to screen patients before organ transplants, detect genetic disorders and infectious diseases, and determine therapy for genetic disorders.

Its administrators hope that Ferris students will master the techniques and fill a demand expressed by hospitals and medical employers around the country for clinical laboratory workers, trained in the burgeoning field of molecular medicine, Ferris said.

Weve heard from people within the field that their labs are looking for students with this certification and who have an education in molecular diagnostics, said Jonathan Karnes, the programs coordinator. Theres a need in the job market for students with this type of degree.

On Wednesday, Nov. 28, students enrolled in Ferris molecular program were preparing for an experiment in which they would examine their own DNA to find out whether they had they had a certain type of gene known as the Alu gene.

Unlike other types of clinical laboratory testing, molecular diagnostics goes beyond the cellular level, and instead checks for ailments on the molecular level, looking for clues in areas such as DNA, Karnes said.

Adam Placer, a senior at Ferris, compared it to solving a puzzle.

I like to trouble shoot, Placer said, and I like to solve problems, and ultimately I like to help people, which is why were here. Related: Ferris State University looks to better serve Latino students Ferris lab, located in GRCCs Applied Technology Center, was completed shortly before fall semester. The university spent $1.4 million to renovate the 3,200-square-foot space and buy equipment. Ferris molecular diagnostics program was created in fall 2011, and its first six students are expected to graduate this spring.

The first three years of the program take place at Ferris main campus in Big Rapids. Students take their fourth year at Ferris new lab in Grand Rapids.

Karnes said the university decided to expand in Grand Rapids because it wanted students to be near the citys Medical Mile. The hope is that students will network and build relationships with medical employers, possibly leading to job offers upon graduation.

See original here:

Ferris State's new Grand Rapids laboratory aims to fill skills gap in Michigan's medical industry

30.11.2012 - (idw) Deutsches Zentrum fr Neurodegenerative Erkrankungen e.V. (DZNE)

Joint Press Release from the German Center for Neurodegenerative Diseases and the University Medical Center Gttingen

Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the University Medical Center Gttingen (UMG) have identified an enzyme as a possible target for the treatment of Alzheimers disease. The protein known as HDAC6 impairs transport processes within the nerve cells. The scientists observed only mild symptoms of the disease in mice if the enzyme was not produced. They propose to block its activity in a targeted fashion to treat the disease. Scientists from the DZNE sites in Gttingen and Bonn, the UMG as well as from the US participated in this basic research project on Alzheimers disease. The study is published in "EMBO Molecular Medicine".

The researchers led by Prof. Andr Fischer, Department of Psychiatry and Psychotherapy at the University Medical Center Gottingen and Site Speaker of the DZNE in Gttingen, investigated mice with a modified genetic background. The animals showed behavioural disorders and brain deposits that are typically associated with Alzheimers disease. The researchers went a step further with a group of other animals by removing the genes responsible for the production of the HDAC6 enzyme (histone deacetylase 6). This intervention proved to be effective: while these mice also exhibited the pathological features of Alzheimers disease in the brain, their behaviour was significantly ameliorated. "The animals ability to learn and to find their spatial bearings was relatively normal", says Prof. Fischer. "Their cognitive abilities were fully comparable to those of healthy mice."

Improved cellular traffic

In the researchers view, this effect is at least partly attributable to the fact that important transport processes within the nerve cells are facilitated when the HDAC6 enzyme is not around. This meant in particular that the cells power plants, also known as "mitochondria", can travel to their final destinations. "It is known that in various neurodegenerative diseases cellular transport is no longer functional. The substances that are to be transported along axons are left behind", Fischer says. "Measures which improve trafficking seem to have a positive effect."

Possible target for therapy?

The researchers findings suggest that the HDAC6 enzyme could be a possible target for therapies against Alzheimers disease. However, treatments would require an active substance that can disable the enzyme in a targeted fashion. Unfortunately, the active substances known to date are too unspecific. Prof. Fischer explains that their application resembles a broad-spectrum treatment: "We dont know precisely what is the therapeutic effect of the inhibitors, since they simultaneously block several enzymes from the histone deacetylase family", he says. "And we still dont know enough about how the individual enzymes function".

Original publication: "Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimers disease", Nambirajan Govindarajan, Pooja Rao, Susanne Burkhardt, Farahnaz Sananbenesi, Oliver M. Schlter, Frank Bradke, Jianrong Lu, Andr Fischer, EMBO Molecular Medicine, online at: http://onlinelibrary.wiley.com/doi/10.1002/emmm.201201923/abstract

The German Center for Neurodegenerative Diseases (DZNE) investigates the causes of diseases of the nervous system and develops strategies for prevention, treatment and care. It is an institution of the Helmholtz Association of German Research Centres with sites in Berlin, Bonn, Dresden, Gttingen, Magdeburg, Munich, Rostock/Greifswald, Tbingen and Witten. The DZNE cooperates closely with universities, their clinics and other research facilities. Its cooperation partners in Gttingen are the Georg-August-University and the University Medical Center Gttingen. Website: http://www.dzne.de/en function fbs_click() {u=location.href;t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;} html .fb_share_link { padding:2px 0 0 20px; height:16px; background:url(http://static.ak.facebook.com/images/share/facebook_share_icon.gif?6:26981) no-repeat top left; } Share on Facebook

See the original post:

Molecular knock-out alleviates Alzheimers symptoms in mice

PHOENIX, Nov. 26, 2012 /PRNewswire/ --

Webcast Advisory

What:

Announcement of a state-of-the-art pediatric medical research institute led by an internationally respected team racing to unlock genomic codes and develop new drug therapies. Their discoveries will lead to biomedical breakthroughs that will give new hope to thousands of pediatric patients facing terminal diagnoses.

Who:

Phoenix Children's Hospital, in collaboration with Translational Genomics Research Institute (TGen) and University of Arizona College of Medicine - Phoenix

When:

1:30 p.m. MST Dec. 4, 2012

Where:

http://www.videonewswire.com/event.asp?id=90997

Read the rest here:

Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients

IEEE HIC 2012 - Keynote - Matthew O #39;Donnell
Matthew O #39;Donnell Frank Julie Jungers, Dean of Engineering, University of Washington Talk Title: Is Molecular Imaging Truly Needed to Translate the Promise of Molecular Medicine into a Clinical Reality? Matthew O #39;Donnell is a native New Yorker with a high-energy, high-humor, fast-paced, and direct manner who has spent most of his academic and professional career in the Midwest. A physicist by training with undergraduate through doctoral degrees from Notre Dame, O #39;Donnell exemplifies the new breed of scientist-engineer who works across disciplines. He joined the University of Michigan faculty in 1990 as a professor of electrical engineering and computer science. In 1998, he was named the Jerry W. and Carol L. Levin Professor of Engineering and was appointed chair of the Biomedical Engineering Department in 1999. He also won several engineering teaching awards at Michigan. An expert in ultrasound imaging, O #39;Donnell #39;s initiated cutting-edge explorations of new imaging modalities in biomedicine, including ultrafast optics, in vivo microscopy, catheter imaging of coronary arteries, optoacoustic arrays, and elasticity and molecular imaging. O #39;Donnell holds 50 patents and has authored or co-authored more than 200 publications. He is associate editor of the journal Ultrasonic Imaging, is a permanent member of the National Institutes of Health Imaging Study Section, a fellow of both IEEE and AIMBE, and a member of Sigma Xi, and the American Physical Society.From:IEEEEMBSViews:0 0ratingsTime:01:19:04More inScience Technology

See the original post:

IEEE HIC 2012 - Keynote - Matthew O'Donnell - Video

Molecular Diagnostics
ll4.me Molecular Diagnostics Key Features #65533; Contains state-of-the-art techniques for the detection of the underlying genetic heterogeneity leading to inherited disorders #65533; Includes in-depth discussion of ethical and safety considerations #65533; Identifies genetically modified organisms (GMO #39;s) #65533; Covers forensic analysis and every-day issues in a diagnostic laboratoryDescriptionThe second edition of Molecular Diagnostics, the only book dealing with diagnosis on a molecular level, discusses current molecular biological techniques used to identify the underlying molecular defects in inherited disease. The book delves further into the principle and brief description of the technique, followed by examples from the authors #39; own expertise. Contributors to the 2/e are well-known experts in their field, and derive from a variety of disciplines, to ensure breadth and depth of coverage. Molecular Diagnostics, 2/e , is a needed resource for graduate students, researchers, physicians and practicing scientists in molecular genetics; professionals from similar backgrounds working in diagnostic laboratories in academia or industry, as well as, academic institutions and hospital libraries.RELATED TITLES:Trent/Molecular Medicine, April 2005,$79.95, 0-12-699057-3 Innis (1999) PCR Applications, HB, $89.95,0-12-372185-7, PB, $66.95,Key Features:*Deals exclusively with the currently used molecular biology techniques to identify the underlying molecular defect of inherited diseases*Includes ...From:melissafudge9865Views:0 0ratingsTime:00:13More inPeople Blogs

Read the rest here:

Molecular Diagnostics - Video

2012-11.17-Ask the Experts- "Living with ALS"
Tune in LIVE on Saturday, November 17 from 3-6 pm Viewers can ask the experts their questions via the "Live Chat" feature or you can send an email to asktheexperts@alsagoldenwest.org Program Schedule: 3:00 pm- Important Aspects in Clinical Care Multidisciplinary Care and ALS Catherine Lomen-Hoerth, MD, PhD Director, The ALS Center at UCSF Communicating with ALS Ilyssa Abaranok, MS CCC-SLP AAC Specialist, The ALS Association Golden West Chapter Meeting Your Mobility Needs David Beals, ATP Brett Zaer, ATP Superior Mobility 5:00 pm - Research Developments Overview of ALS Research Lucie Bruijn, PhD Chief Scientist, The ALS Association Genetics of ALS Robert H Baloh, MD, PhD Director, Cedars-Sinai ALS Center Novel Approaches, Therapies, and Genes Don W. Cleveland, PhD Departmental Chair of Cellular and Molecular Medicine University of California, San Diego Stem Cells and ALS Clive Svendsen, PhD Director, Cedars-Sinai RMIFrom:alsagoldenwestViews:131 0ratingsTime:02:12:48More inNonprofits Activism

Read the original here:

2012-11.17-Ask the Experts- "Living with ALS" - Video

SAN DIEGO, Nov. 12, 2012 /PRNewswire/ --Sequenom, Inc. (SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

This Sequenom CMM laboratory-developed genetic test (LDT) combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization (CNV) disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration (AMD), in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately 10 percent of AMD patients, but is associated with 90 percent of vision loss in AMD.

The clinical validation of the laboratory test predicting progression to CNV was conducted using patient DNA samples made available through the National Eye Institute's Age-Related Eye Disease Study (AREDS). More than 2,000 patients were genotyped for 13 single nucleotide gene polymorphisms (SNPs) in genes previously shown to be associated with CNV. Sequenom CMM compared the predictive value of a phenotype model, based on the assessment of disease grade currently used in clinical practice. The predictive model that combined genotype with phenotype was found to be more accurate in predicting CNV progression (AUC=0.96) than the phenotype model alone based on disease grade (AUC=0.89), concluding that inclusion of the genotype assessment is more effective in predicting CNV progression compared with phenotype alone.

"Physicians today rely on an assessment of patient disease stage to predict the risk of progressing to CNV, and this genetic laboratory developed test will help improve the accuracy of prediction by assessing individual risk based on the genetic predisposition of the patient," said Allan T. Bombard, M.D., Sequenom's Chief Medical Officer.

The study was conducted in compliance with the Coriell Cell Repositories Institutional Review Board, in accordance with Department of Health and Human Services (45 CFR Part 46). The dataset used for the analysis was obtained from the National Eye Institute-Age-Related Eye Disease Study (NEI-AREDS) Genetic Repository. Funding support for AREDS was provided by the National Eye Institute grant N01-EY-0-2127, National Institutes of Health, Bethesda, Maryland.

At the meeting: Paper 30031594: Combining Genotype and Phenotype to Predict Progression to Choroidal Neovascularization (CNV) in Patients with AMD (Presented Monday, November 12, 3:42 PM in S406B)

About SequenomSequenom, Inc. (SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Sequenom CMM, LLCSequenom Center for Molecular Medicine (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory-developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists, maternal fetal medicine specialists, retinal specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the benefits or expectations of Sequenom CMM's genetic AMD test including the test's ability to help improve the accuracy of predicting the risk of a patient progressing to CNV by assessing individual risk based on the genetic predisposition of the patient, Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products and to scale up its operations to meet increased product demand, particularly for new technologies and products such as Sequenom CMM's prenatal and other diagnostics testing services, Sequenom's ability to manage its existing cash resources or raise additional cash resources, customer demand, Sequenom's ability to obtain payor reimbursement and payment collection and the timing thereof, for Sequenom CMM's diagnostic test services including the MaterniT21 PLUS LDT, Sequenom's ability to convert to accrual accounting for its diagnostic test services including the MaterniT21 PLUS LDT, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation asserting infringement by our products or challenging the validity of our patents, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly Report on Securities and Exchange Commission Form 10-Q and Annual Report on Securities and Exchange Commission Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Read more here:

Study Shows Sequenom CMM's RetnaGene LDT Accurately Predicts Risk of Progression to Wet Form of AMD

Sengenics Announces Exclusive Agreement with the Sequenom Center for Molecular Medicine to Provide Its Non-Invasive Prenatal Trisomy Test in Malaysia and Singapore

Sengenics will work with medical practitioners in the region to prescribe MaterniT21 PLUS for the detection of Trisomy 13, 18 and 21 in expectant mothers. Sengenics has a strong regional footprint and has established channels into the medical sector, with 8 out of ten of the top private hospital chains in the region currently under contract.

We are delighted to be working with Sequenom CMM, particularly given their success with MaterniT21 PLUS in North America and around the world, a very important consideration for us, said Dr. Arif Anwar, Executive Director, Sengenics. The test has been widely peer-reviewed, validated and published as the most accurate test for diagnosing the existence of trisomy 21, an indication of Downs syndrome.

MaterniT21 PLUS is now available through Sengenics select panel of partner O&G Clinicians and Hospitals in Malaysia and Singapore.

About Sengenics Founded in 2008, Sengenics was the 1st company in Asia to offer genomics based diagnostics services. Since its inception, Sengenics has focused upon building key research collaborations and diagnostics facilities throughout Asia. The company has an exclusive strategic partnership with Oxford University Professor Sir Edwin Southerns company, Oxford Gene Technology (OGT) for Asia.

In addition to providing research and diagnostics services, Sengenics continues to develop its own IP and downstream genomics, proteomics and antibody biomarker based tests.

About Sequenom CMM, LLC Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists, and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Sengenics Enquiries to Mohd Badzlan http://www.sengenics.com enquiries@sengenics.com

Go here to see the original:

Sengenics Announces Exclusive Agreement with the Sequenom Center for Molecular Medicine to Provide Its Non-Invasive ...

SAN DIEGO--(BUSINESS WIRE)--

Illumina, Inc. (ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris evidence-based molecular profiling service. The MiSeq system will be deployed to enablerapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illuminas amplicon-based assay.

Caris Life Sciences molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information. Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients. The addition of next-generation sequencing to Caris molecular profiling service represents the next step in the natural evolution of this cutting-edge offering.

We are pleased to be the selected sequencing platform for Caris Life Sciences, an unmatched leader in tumor profiling, whose molecular profiling service has been ordered for more than 40,000 patients to date, said Matt Posard, Senior Vice President and General Manager of Illuminas Translational and Consumer Genomics business. This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes.

Caris Life Sciences is one of the few entities to offer next-generation sequencing commercially in their CLIA-accredited laboratory, and will replace its current sequencing technology with Illuminas MiSeq system. The addition of next-generation sequencing via the MiSeq complements the variety of highly integrated technology platforms already employed by Caris, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR). Caris molecular profiling service uses these cutting-edge technologies to comprehensively interrogate the entire cancer biological process including DNA, RNA, and protein analysis.

Caris leverages the most clinically relevant technologies and biomarkers to help physicians individualize care. When we choose to add a new technology to our portfolio, we are committed to selecting a best-in-class platform and partner, as evidenced by our selection of Illumina, said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences. After a thorough evaluation of top NGS platforms, Illuminas data quality, simple workflow, and commitment to a collaborative approach were key to our decision to work with them.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic, and theranostic services. The companys evidence-based molecular profiling service matches molecular data generated from a patients tumor with biomarker/drug associations derived from the worlds leading clinical cancer literature. This service uses the most advanced and clinically relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the companys proprietary Carisome platform a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like molecular profiling and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit http://www.carislifesciences.com.

More here:

Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular ...

Stem Cells and the Future of Medicine - Larry Goldstein, Ph.D. at TEDxAmericasFinestCity
Dr. Goldstein is a Professor of Cellular and Molecular Medicine at the University of California, San Diego, School of Medicine. He received his BA degree in biology and genetics at UCSD and his Ph.D. degree in genetics from the University of Washington, Seattle. He did his postdoctoral work at the University of Colorado at Boulder and the Massachusetts Institute of Technology. Prior to moving to UCSD, he was Professor of Cellular and Developmental Biology at Harvard University.From:TEDxTalksViews:240 13ratingsTime:16:15More inScience Technology

Follow this link:

Stem Cells and the Future of Medicine - Larry Goldstein, Ph.D. at TEDxAmericasFinestCity - Video

Education Book Review: Systems Biology (Current Topics from the Encyclopedia of Molecular Cell Bi...
http://www.EducationBookMix.com This is the summary of Systems Biology (Current Topics from the Encyclopedia of Molecular Cell Biology and Molecular Medicine) by Robert A. Meyers.From:EducationBookReviewsViews:0 0ratingsTime:01:27More inEntertainment

See the article here:

Education Book Review: Systems Biology (Current Topics from the Encyclopedia of Molecular Cell Bi... - Video

CTMM Nieuwspoortdebat 9 okt 2012 small FINAL
CTMM Nieuwspoortdebat 9 oktober 2012: #39;Keuzes in de Gezondheidszorg #39; Topsectorenbeleid medische technologie een wassen neus Hoe houden we de gezondheidszorg betaalbaar, van hoogstaande kwaliteit en voor iedereen toegankelijk? Dat was het centrale thema van een debat dat CTMM (Center for Translational Molecular Medicine) 9 oktober in perscentrum Nieuwspoort organiseerde. Conclusie: de overheid moet veel meer geld investeren in het topsectorenbeleid rond medische technologie. "Want dat is nu pure window dressing", aldus Jan Raaijmakers, Vice President External Scientific Collaborations Europe van GlaxoSmithKline. Om nieuwe, kostbare geneesmiddelen en therapien te kunnen blijven aanbieden, is er een urgente behoefte om de effectiviteit daarvan beter te kunnen voorspellen, zo vonden de deelnemers aan het debat. Tegelijkertijd zijn nieuwe methoden om ziekten in een vroeger stadium op te sporen dringend gewenst. Zoals Tom Oostrom, directeur van de Nierstichting en voorzitter van de Samenwerkende Gezondheidsfondsen het verwoordde: "Vroegdiagnostiek werkt kostenbesparend. Als mensen eenmaal klachten hebben, vallen de ziektekosten veel hoger uit. Zo kost nierdialyse jaarlijks maar liefst 80.000 euro per patint." En hoogleraar Cardiologie Yigal Pinto (AMC): "Er is enorm veel te winnen als je eerder kunt ingrijpen." Meer investeren in medische innovatie is dus dringend gewenst, concludeerde onder andere Jan Raaijmakers. "Nu is het topsectorenbeleid voor de medische technologie een ...From:Marjoke op het WerkViews:51 0ratingsTime:06:08More inNews Politics

More:

CTMM Nieuwspoortdebat 9 okt 2012 small FINAL - Video

Nobel Laureate Dr James Watson Speech
Lecture of Academic Excellence "From the Double Helix to the Curing of Cancer" at the Inauguration Ceremony of the Cyprus School of Molecular Medicine.From:CINGCSMMViews:177 4ratingsTime:01:01:08More inScience Technology

Excerpt from:

Nobel Laureate Dr James Watson Speech - Video

Cyprus School of Molecular Medicine
The Dean of the Cyprus School of Molecular Medicine, Professor Leonidas Phylactou, speaks to CyBC news show Apo Mera se Mera about the newly established School of the Cyprus Institute of Neurology and Genetics.From:CINGCSMMViews:48 0ratingsTime:04:42More inScience Technology

See original here:

Cyprus School of Molecular Medicine - Video

Cyprus School of Molecular Medicine - Press Conference March 2012
News feature on MEGA channel about the Cyprus School of Molecular Medicine, a school of the Cyprus Institute of Neurology and Genetics.From:CINGCSMMViews:52 2ratingsTime:01:45More inScience Technology

Originally posted here:

Cyprus School of Molecular Medicine - Press Conference March 2012 - Video